SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.…
SLS Stock Suffers Worst Rout Since January After $150M Share Sale — But Fresh Filing Has Retail Bulls Saying Sellas Has More Buyout Leverage
SELLAS Life Sciences Group (NASDAQ: SLS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 13 employees.
The shares were at 13.66 USD on 20 November 2026, up 743.2% over 52 weeks. Its 52-week range is 1.390 USD to 24.89 USD: the price is 45.1% below the high and 882.7% above the low.
Its market capitalisation is 2.78B USD.
SELLAS Life Sciences Group reports return on equity of -37.9% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 134.11M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 2 analysts cover the stock, with an average rating of Buy; their mean price target of 37.50 USD is 174.5% above the current price. The next earnings report is expected on 18 March 2027.